Updates are available Correction dated 2021-06-17
Click to view Correction: https://doi.org/10.1038/s41576-021-00384-2
-
Authors
Silver, Alexander J. https://orcid.org/0000-0001-8255-3140
Bick, Alexander G. https://orcid.org/0000-0001-5824-9595
Savona, Michael R. https://orcid.org/0000-0003-3763-5504
- License Information
-
More Information
Article History
Accepted: 23 March 2021
First Online: 13 May 2021
Change Date: 17 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41576-021-00384-2
Competing interests
: A.J.S. and A.G.B. declare no competing interests. M.R.S. receives research funding from ALX Oncology, Astex, Incyte, Takeda and TG Therapeutics; has equity with Karyopharm; and serves as an advisor or consultant to AbbVie, Astex, BMS, Geron, Incyte, Karyopharm, Ryvu, Sierra Oncology, Takeda, Taiho and TG Therapeutics.
